KIYATEC

KIYATEC has developed primary human derived 3D microtumors designed to more accurately predict human response to cancer drugs in an ex vivo system. The heterotypic, 3D perfused co-cultures established the use of a systemic strategy of adopting optimized scaffolds, cell types, and media conditions to KIYATEC’s novel 3D perfusion bioreactor, the 3DKUBE™.
Website: kiyatec.com

Get Exclusive Access to the Top PMWC Talks

To receive the most comprehensive news and updates from the field of precision medicine, subscribe to the newsletter here.

Bonus for suscribing, you will get the access code for the top 3 talk videos from January's Precision Medicine World Conference.

You have successfully subscribed, you can access the talks here.

We hate spam too, unsubscribe at any time.

Do not alert me again.